Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Commentary

HIV incidence among injection drug users in Vancouver

Robert S. Remis
CMAJ April 02, 2002 166 (7) 908-909;
Robert S. Remis
Dr. Remis is Associate Professor, Department of Public Health Sciences, University of Toronto, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

In this issue (page 894), Patricia Spittal and colleagues report that HIV incidence among injection drug users (IDUs) in Vancouver's Downtown Eastside appears to be greater among women than among men.1 As the authors point out, this is an unusual finding and grounds for concern. Although not emphasized in the report, HIV infection rates were substantially higher, about twice as high, among both male and female Aboriginal IDUs compared with non-Aboriginals. As a substantially higher proportion of women in the study self-reported identification as an Aboriginal, 41.0% compared with 16.5% for the men, much of the observed difference was probably related to Aboriginal status. In fact, the cumulative HIV incidence rate among Aboriginal subjects was 19.0% (19.4% for women and 18.4% for men) compared with 9.3% among non-Aboriginal subjects (11.3% in women and 8.6% for men). Thus, a very important interpretation of their study is that HIV rates were higher among Aboriginal IDUs.

Aside from the issue of Aboriginal status, women appear to have been at somewhat increased risk of HIV seroconversion. This may have been related to sexual exposure to HIV infection; in fact, both unsafe sex with a regular partner and having an HIV-positive partner were independently associated with infection among women, but not among men. In other studies, women have been found to be at higher risk of infection from sex than men2 for biologic and perhaps other reasons. This should be a significant part of both the interpretation of the results and consideration of the public health implications.

Beyond the finding of the high HIV incidence observed among women, which is related mostly to a high rate among Aboriginals, the most important finding of the study is the continuing high rates of transmission of HIV among IDUs in Vancouver. Based on estimates from the Kaplan-Meier analysis presented in the paper, annual HIV infection rates were in the range of 3%–5%. For some reason, the rates were substantially higher in the first 6 months following recruitment into the study (12%–18% annual rate) compared with later on (about 2%–3%); it is unclear whether this is a cohort or a calendar effect. Nevertheless, even an incidence of 2% is exceedingly high; HIV infection is still serious and potentially fatal and only in part mitigated by effective antiretroviral regimens. Furthermore, use of these regimens among injection drug–using populations who continue to inject presents major challenges with respect to adherence: studies have shown that adherence must be exceptionally high (>> 95%) for such regimens to be effective.3 Thus, this high rate of HIV transmission reflects a catastrophic situation that, if sustained, will cause thousands of IDUs in Vancouver alone to acquire this infection over the next decade, with untold cost in expenses for medical and other support services as well as in human misery. Despite the fact that Vancouver has one of the highest volumes of needle exchange in Canada and the world, HIV transmission continues to occur at an alarming rate.

The observations from this and other similar studies must cause us to reassess our current strategy for controlling HIV infection. First, we must reconsider the legal framework of society's response to substance abuse, in general, and injection drug use, in particular. Clearly, the expensive and resource-draining activities devoted to the enforcement of Canada's drug laws must be seriously questioned. This is the current preoccupation of the House of Commons Special Committee on the Non-Medical Use of Drugs, which is currently in the process of gathering information through national hearings. We will need to be particularly wise and open-minded about considering different and potentially more effective modifications to our drug laws and their enforcement. It is probably opportune to consider decriminalizating simple possession and treating substance abuse primarily as a medical and public health problem rather than a criminal one. Society should hesitate to put such efforts into censuring behaviour that, in a direct sense, has no other victim than the person himself or herself.

The development and implementation of “safe injection sites” is an intriguing option that may be of some benefit to a subset of the IDU population.4 The efficacy, effectiveness and efficiency of such an approach remain, however, to be demonstrated. It may be that the people who need such facilities most are in a chaotic and disorganized state and are not likely to use them. Nevertheless, I believe that safe injection sites are a worthwhile option that deserves to have a systematic and rigorous evaluation.

The accessibility of services at all thresholds must also be seriously reassessed. Needle exchanges should do far more than provide needles; they should be the port of entry into a care system that can help many, though not all, in a vulnerable population to deal effectively with their addiction. In many parts of the country, waiting lists for detoxification programs are long and deter individuals who are ready to deal with their addiction from doing so. Obstacles to individuals' access to detoxification and rehabilitation must be removed

Finally, we must seriously re-examine our social policy, especially in the context of the Aboriginal population. Current policies create the conditions for social degeneration and disorganization that lead to multiple psychological and social problems, including injection drug use. We must fully involve addicted individuals in efforts to identify new and potentially effective means to address the problem of addiction, as well as to increase the proportion of injections that are free from the risk of HIV and other serious bloodborne infections.

Unfortunately, it is difficult to be hopeful in this regard. Similar observations were made in a study from the same group almost exactly 5 years ago,5 following the first wave of high HIV incidence among IDUs in Vancouver. One has to wonder what it will take for policy-makers to deal seriously with this problem.

𝛃 See related article page 894

Footnotes

  • Competing interests: None declared.

References

  1. 1.↵
    Spittal PM, Craib KJP, Wood E, Laliberté N, Li K, Tyndall MW, et al. Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ 2002;166(7):894-9.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Padian NS, Shiboski SC, Glass SO, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. Am J Epidemiol 1997;147:350-7.
    OpenUrl
  3. 3.↵
    Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Unsafe injection practices in a cohort of injection drug users in Vancouver: Could safer injection rooms help? CMAJ 2001;165(4):405-10.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Strathdee SA, Patrick DM, Currie SL, Cornelisse PG, Rekart ML, Montaner JS, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997;11(8):F59-65.
PreviousNext
Back to top

In this issue

CMAJ
Vol. 166, Issue 7
2 Apr 2002
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
HIV incidence among injection drug users in Vancouver
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
HIV incidence among injection drug users in Vancouver
Robert S. Remis
CMAJ Apr 2002, 166 (7) 908-909;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
HIV incidence among injection drug users in Vancouver
Robert S. Remis
CMAJ Apr 2002, 166 (7) 908-909;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights of this issue
  • Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver
  • PubMed
  • Google Scholar

Cited By...

  • Decriminalizing nonmedical drug use
  • Google Scholar

More in this TOC Section

  • Transforming race-based health research in Canada
  • Not neutral: reimagining antiracism as a professional competence
  • Time to dismantle systemic anti-Black racism in medicine in Canada
Show more Commentary

Similar Articles

Collections

  • Topics
    • HIV & AIDS
    • Addiction medicine

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire